[Piperacillin in the treatment of suppurative inflammatory complications in cancer patients].
Piperacillin (Pipril, Lederle, USA) is semisynthetic penicillin highly active against aerobic and anaerobic organisms. Its high activity was demonstrated with respect to 289 strains of aerobes, 82.7 per cent of the Pseudomonas aeruginosa strains being susceptible to Pipril. Diverse purulent inflammatory complications were treated with Pipril in doses of 8 to 24 g a day in 27 patients with malignant tumors. The clinical effect in 84.6 per cent of the cases was recorded. Complete elimination of the pathogens was observed in 73.5 per cent of the patients. Therefore, Pipril should be considered as one of the most active antibiotics for the treatment of purulent inflammatory complications in oncological patients.